L-371,257

L-371,257
L-371,257
L-371,257.svg
임상 데이터
루트
행정부.		입으로
ATC 코드
  • 없음.
식별자
  • 1-[(4-[(1-아세틸-4-피페리디닐)옥시]-2-메톡시벤조일]-4-(2-옥소-2H-3,1-벤조옥사진-1(4-H)-일)피페리딘
CAS 번호
PubChem CID
IUPHAR/BPS
켐스파이더
첸블
CompTox 대시보드 (EPA )
화학 및 물리 데이터
공식C28H33N3O6
몰 질량507.587g/120−1
3D 모델(JSmol)
  • O=C1OCC3cc3N1C(CC4)CCN4C(=O)c2cc(cc2)OC)OC5CCN(C(C)=O)CC5
  • InChI=1S/C28H33N3O6/c1-19(32)29-15-11-22(12-16-29)37-23-7-8-24(26)35-2)27(33)30-139-21)31-256-4-255(32)
  • 키: WDERJSQJYIJOPD-UHFFFAOYSA-N ☒N
☒NcheckY (이게 뭐죠?) (표준)

L-371,257은 관련된 바소프레신 [1]수용체보다 800배 이상의 선택성을 가진 옥시토신 수용체의 선택적 길항제 역할을 하는 과학 연구에 사용되는 화합물이다.그것은 개발된 최초의 [2][3][4][5]비펩타이드 옥시토신 길항제 중 하나였으며, 경구 생체 가용성은 좋으나 혈액-뇌 장벽의 침투는 저조하여 중심 부작용이 [6]거의 없는 양호한 말초 선택성을 제공한다.잠재적 적용은 조기 [7]분만을 치료하는 데 있을 가능성이 높다.

「 」를 참조해 주세요.

레퍼런스

  1. ^ Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, et al. (November 1995). "1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist". Journal of Medicinal Chemistry. 38 (23): 4634–6. doi:10.1021/jm00023a002. PMID 7473590.
  2. ^ Bell IM, Erb JM, Freidinger RM, Gallicchio SN, Guare JP, Guidotti MT, et al. (June 1998). "Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines". Journal of Medicinal Chemistry. 41 (12): 2146–63. doi:10.1021/jm9800797. PMID 9622556.
  3. ^ Kuo MS, Bock MG, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, et al. (November 1998). "Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus". Bioorganic & Medicinal Chemistry Letters. 8 (21): 3081–6. doi:10.1016/S0960-894X(98)00568-X. PMID 9873680.
  4. ^ Williams PD, Bock MG, Evans BE, Freidinger RM, Gallicchio SN, Guidotti MT, et al. (May 1999). "Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency". Bioorganic & Medicinal Chemistry Letters. 9 (9): 1311–6. doi:10.1016/S0960-894X(99)00181-X. PMID 10340620.
  5. ^ Wyatt PG, Allen MJ, Chilcott J, Foster A, Livermore DG, Mordaunt JE, et al. (May 2002). "Identification of potent and selective oxytocin antagonists. Part 1: indole and benzofuran derivatives". Bioorganic & Medicinal Chemistry Letters. 12 (10): 1399–404. doi:10.1016/S0960-894X(02)00159-2. PMID 11992786.
  6. ^ Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, et al. (April 2006). "Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications". Psychopharmacology. 185 (2): 218–25. doi:10.1007/s00213-005-0293-z. PMID 16418825. S2CID 13647805.
  7. ^ Hawtin SR, Ha SN, Pettibone DJ, Wheatley M (January 2005). "A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists". FEBS Letters. 579 (2): 349–56. doi:10.1016/j.febslet.2004.10.108. PMID 15642343. S2CID 38088139.